Patents by Inventor Steven A. Rosenberg

Steven A. Rosenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
    Patent number: 10251912
    Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: April 9, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rong-Fu Wang, Steven A. Rosenberg, Gang Zeng
  • HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS
    Publication number: 20190085046
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: September 19, 2018
    Publication date: March 21, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Rami Yoseph, Gal Cafri, Paul F. Robbins, Steven A. Rosenberg
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS
    Publication number: 20190085047
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: November 30, 2018
    Publication date: March 21, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Service
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY
    Publication number: 20190060363
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Application
    Filed: November 6, 2018
    Publication date: February 28, 2019
    Inventors: Branden MORIARITY, Beau WEBBER, Modassir CHOUDHRY, Steven A. ROSENBERG, Douglas C. PALMER, Nicholas P. RESTIFO
  • INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY
    Publication number: 20190060364
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Application
    Filed: November 6, 2018
    Publication date: February 28, 2019
    Inventors: Branden MORIARITY, Beau WEBBER, Modassir CHOUDHRY, Steven A. Rosenberg, Douglas C. PALMER, Nicholas P. RESTIFO
  • ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE
    Publication number: 20190054143
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 21, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Richard A. Morgan, Dhanalakshmi Dhanalakshmi, Steven A. Rosenberg
  • INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY
    Publication number: 20190054122
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Application
    Filed: November 5, 2018
    Publication date: February 21, 2019
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS
    Publication number: 20190040111
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: September 9, 2016
    Publication date: February 7, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Service
    Inventors: Eric Tran, Yong-Chen Lu, Steven A. Rosenberg
  • METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF
    Publication number: 20190032011
    Abstract: Provided herein are methods for manufacturing T cells. In certain embodiments, methods for manufacturing T cells which express a cell surface receptor that recognizes a specific antigenic moiety on the surface of a target cell are provided.
    Type: Application
    Filed: June 18, 2018
    Publication date: January 31, 2019
    Inventors: Marc Better, Steven A. Feldman, Steven A. Rosenberg
  • T CELL RECEPTORS RECOGNIZING HLA-A1- OR HLA-CW7-RESTRICTED MAGE
    Publication number: 20190016777
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 17, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Paul F. Robbins, Steven A. Rosenberg, Shiqui Zhu, Steven A. Feldman, Richard A. Morgan
  • TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY
    Publication number: 20190008899
    Abstract: Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.
    Type: Application
    Filed: April 6, 2018
    Publication date: January 10, 2019
    Inventors: Branden MORIARITY, Beau WEBBER, Modassir CHOUDHRY, Steven A. ROSENBERG, Douglas C. PALMER, Nicholas P. RESTIFO
  • Anti-human papillomavirus 16 E7 T cell receptors
    Patent number: 10174098
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: January 8, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Intracellular genomic transplant and methods of therapy
    Patent number: 10166255
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: January 1, 2019
    Assignees: REGENTS OF THE UNIVERSITY OF MINNESOTA, INTIMA BIOSCIENCE, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES
    Inventors: Branden Moriarity, Beau Webber, R. Scott McIvor, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • MURINE ANTI-NY-ESO-1 T CELL RECEPTORS
    Publication number: 20180371050
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.
    Type: Application
    Filed: August 29, 2018
    Publication date: December 27, 2018
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Maria R. Parkhurst, Richard A. Morgan, Steven A. Rosenberg, Shannon Faith Rosati
  • METHODS OF CONDITIONING PATIENTS FOR T CELL THERAPY
    Publication number: 20180369283
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Application
    Filed: April 10, 2018
    Publication date: December 27, 2018
    Applicants: Kite Pharma, Inc., United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
  • MARKERS FOR CORONARY ARTERY DISEASE AND USES THEREOF
    Publication number: 20180356432
    Abstract: Markers and methods useful for assessing coronary artery disease in a subject are provided, along with related kits, systems, and media. Also provided are predictive models, based on the markers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.
    Type: Application
    Filed: August 31, 2016
    Publication date: December 13, 2018
    Inventors: Philip BEINEKE, James A. WINGROVE, Karen FITCH, Steven ROSENBERG, Andrea M. JOHNSON
  • DIAGNOSTIC METHODS FOR T CELL THERAPY
    Publication number: 20180344767
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 6, 2018
    Applicants: Kite Pharma, Inc., The United States of America as represented by the Secretary Department of Health and Human Services
    Inventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
  • Anti-SSX-2 T cell receptors and related materials and methods of use
    Patent number: 10143724
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: December 4, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard A. Morgan, Nachimuthu Chinnasamy, Steven A. Rosenberg
  • Composite polyamide membrane made via interfacial polymerization using a blend of non-polar solvents
    Patent number: 10137418
    Abstract: A method for making a composite polyamide membrane comprising a porous support and a thin film polyamide layer, wherein the method includes: i) applying a polar solution comprising a polyfunctional amine monomer, and a non-polar solution comprising a polyfunctional acyl halide monomer to a surface of a porous support and interfacially polymerizing the monomers to form a thin film polyamide layer, wherein the non-polar solution further comprises at least 50 vol % of a C5 to C20 aliphatic hydrocarbon and from 2 to 25 vol % of benzene or benzene substituted with one or more C1 to C6 alkyl groups; and ii) applying an aqueous solution of nitrous acid to the thin film polyamide layer.
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: November 27, 2018
    Assignee: DOW GLOBAL TECHNOLOGIES LLC
    Inventors: Abhishek Roy, Yasushi Maeda, Mou Paul, Steven Rosenberg, Ian A. Tomlinson
  • Murine anti-NY-ESO-1 T cell receptors
    Patent number: 10087230
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: October 2, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Maria R. Parkhurst, Richard A. Morgan, Steven A. Rosenberg, Shannon Faith Rosati